Connection

Andrea Isidori to Cyclic Nucleotide Phosphodiesterases, Type 5

Back to Details
This is a "connection" page, showing publications Andrea Isidori has written about Cyclic Nucleotide Phosphodiesterases, Type 5.
Andrea Isidori
Connection Strength
1.402
Cyclic Nucleotide Phosphodiesterases, Type 5
  1. Targeting the NO-cGMP-PDE5 pathway in COVID-19 infection. The DEDALO project. Andrology. 2021 01; 9(1):33-38.
    View in: PubMed
    Score: 0.867
  2. Chronic phosphodiesterase type 5 inhibition has beneficial effects on subcutaneous adipose tissue plasticity in type 2 diabetic mice. J Cell Physiol. 2018 11; 233(11):8411-8417.
    View in: PubMed
    Score: 0.187
  3. Identification of murine phosphodiesterase 5A isoforms and their functional characterization in HL-1 cardiac cell line. J Cell Physiol. 2018 Jan; 233(1):325-337.
    View in: PubMed
    Score: 0.175
  4. Phosphodiesterase-5 inhibition preserves renal hemodynamics and function in mice with diabetic kidney disease by modulating miR-22 and BMP7. Sci Rep. 2017 03 15; 7:44584.
    View in: PubMed
    Score: 0.172
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.